The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here? Tracy et al., 2021, Journal of Substance Abuse Treatment.
Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review, Adams et al., 2021, Addiction Science & Clinical Practice.
Opioid Toxidrome Following Grapefruit Juice Consumption in the Setting of Methadone Maintenance, Ershad et al., 2020, Journal of Addiction Medicine.
Factors associated with opioid overdose during medication-assisted treatment: How can we identify individuals at risk? Au et al., 2021, Harm Reduction Journal.
Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department, Hawk et al., 2021, Annals of Emergency Medicine.
Mobile methadone dispensing in Delhi, India: implementation research, Rao et al., 2021, Bulletin of the World Health Organization.
The state of harm reduction in prisons in 30 European countries with a focus on people who inject drugs and infectious diseases, Stöver et al., 2021, Harm Reduction Journal.
Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy, Schmidbauer et al., 2021, PLOS One.
The epidemic of fentanyl misuse and overdoses: challenges and strategies, Volkow, 2021, World Psychiatry.
Opioid utility function: methods and implications, Jan van Dam et al., 2020, Annals of Palliative Medicine.
Opioid Therapy in Acute and Chronic Pain, Nafziger et al., 2018, The Journal of Clinical Pharmacology.
When less is more: Opioid use in the emergency department, Patanwala, 2019, American Journal of Health-System Pharmacy.
Estimation of the Social Costs of Illegal Drug Use in Poland Using Standardized Methodology, Mielecka-Kubie, 2020, The Journal of Mental Health Policy and Economics.
Use of cognitive enhancers: methylphenidate and analogs, Carlier et al., 2019, European Review for Medical and Pharmaceutical Sciences.
Reprint of: Biotechnologies and the future of opioid addiction treatments, Wolfe et al., 2021, International Journal of Drug Policy.
Quality of Life in Opioid Replacement Therapy: A Naturalistic Cross-Sectional Comparison of Methadone/Levomethadone, Buprenorphine, and Diamorphine Patients, Guillery et al., 2021, European Addiction Research.
Reorganization of Substance Use Treatment and Harm Reduction Services During the COVID-19 Pandemic: A Global Survey, Radfar et al., 2021, Frontiers in Psychiatry.
The Role of Risk or Contributory Death Factors in Methadone-Related Fatalities: A Review and Pooled Analysis, Giorgetti et al., 2021, Metabolites.
Methadone overdose in patients following methadone mainte-nance treatment:A three years overview in the district of Bari (South-Italy), Favia et al., 2021, Clinica Terapeutica.
Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report, Palis et al., 2021, Harm Reducation Journal.
Non-medical Use of Prescription Gabapentinoids (Gabapentin and Pregabalin) in Five European Countries, Fonseca et al., 2021, Frontiers in Psychiatry.
International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder, Özgen et al., 2020, European Addiction Research.
Availability of Illegal Drugs During the COVID-19 Pandemic in Western Germany, Scherbaum et al., 2021, Frontiers in Psychiatry.
Drug-related deaths and mortality in EuropeUpdate from the EMCDDA expert network, European Monitoring Centre for Drugs and Drug Addiction, 2021.
Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway, Chalabianloo et al., 2021, Substance Abuse Treatment, Prevention, and Policy.
Gender Differences on Methadone Maintenance Treatment Outcome among Patients with Opioid use Disorder: A Systematic Review, Rizal et al., 2020, Journal of Pharmacy & BioAllied Sciences.
Prevalence and Characteristics of Chronic Pain in Buprenorphine and Methadone-Maintained Patients, Delorme et al., 2021, Frontiers in Psychiatry.
Benzodiazepine Use in Opioid Maintenance Treatment Programme: Risks and Clinical Outcomes, Oliveira et al., 2021, Acta médica portuguesa.
Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis, Santo et al., 2021, JAMA Psychiatry.
Considering the harms of our habits: The reflexive urine drug screen in opioid use disorder treatment, Khatri et al., 2020, Journal of Substance Abuse Treatment.
Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies, Fava et al., 2020, Molecular Psychiatry.
Substitution treatment for opioid dependence with slow-release oral morphine: Retention rate, health status, and substance use after switching to morphine, Lehmann el al., 2021, Journal of Substance Abuse Treatment.
Methadone, Metoclopramide and Metronidazole Interaction Causing Torsades de Pointes, Gnanapandithan el al., 2021, Clinics and Practice.
Behandlung opioidabhängiger Inhaftierter – Einstellungen und Behandlungspraxis des medizinischen Personals in bayerischen Justizvollzugsanstalten, Weiss et al., 2021, Gesundheitswesen.
Empfehlungen zur substitutionsgestützten Behandlung bei Minderjährigen, Erbas et al., 2021, Bayerische Akademie für Sucht- und Gesundheitsfragen.
Factors Associated with Low Bone Density in Opioid Substitution Therapy Patients: A Systematic Review, Ramli et al., 2021, International Journal of Medical Sciences.
Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine, Lintzeris et al., 2021, JAMA Network Open.
Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors, Beard et al., 2021, Addiction.
Folgen der COVID-19-Pandemie für Menschen mit Schizophrenie, Demenz und Abhängigkeitserkrankungen, Adorjan et al., 2021, Nervenarzt.
COVID‐19 Vaccination among socially vulnerable people who use drugs, Arcadepani et al., 2021, Addiction.
Addiction as a brain disease revised: why it still matters, and the need for consilience, Heilig et al., 2021, Neuropsychopharmacology.
Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis, Stone et al., 2021, Lancet Psychiatry.
Prolonged-release buprenorphine formulations: Perspectives for clinical practice, Chappuy et al., 2020, Therapie.
Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis, Link et al., 2020, American Journal of Obstetrics & Gynecology.
The dopamine theory of addiction: 40 years of highs and lows, Nutt et al., 2015, Nature Reviews Neuroscience.
Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone, Rolland et al., 2021, Drug and Alcohol Dependence.
Abuse‐deterrent extended‐release oxycodone and risk of opioid‐related harm, Paljarvi et al., 2021, Addiction.
Tapentadol:An Opioid of Abuse Acquired Online, Ansley et al., 2020, The Primary Care Companion for CNS Disorders
Mindfulness meditation improves emotion regulation and reduces drug abuse, Tang et al., 2016, Drug and Alcohol Dependence.
Ibogaine and addiction in the animal model, a systematic review and meta-analysis, Belgers et al., 2016, Translational Psychiatry.
Dopaminylation of histone H3 in ventral tegmental area regulates cocaine seeking, Lepack et al., 2020, Science.
Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency, Wenzel et al., 2021, Journal of Substance Abuse Treatment.
Filling the Gaps: Planning for the Disaster Health Needs of Patients Taking Opioids and People Using Illicit Drugs
Estimated televised alcohol advertising exposure in the past year and associations with past 30-day drinking behavior among American adults: results from a secondary analysis of large-scale advertising and survey data, Niederdeppe et al., 2021, Addiction.
Peer recovery coaches in general medical settings: Changes in utilization, treatment engagement, and opioid use, Magidson et al., 2021, Journal of Substance Abuse Treatment.
Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada, Morin et al., 2020, The International Journal on Drug Policy.
Creating an ethical culture to support recovery from substance use disorders, Williamson, 2020, Journal of Medical Ethics.
Is substance use changing because of the COVID‐19 pandemic? Conceptual and methodological considerations to delineating the impact of the Covid‐19 pandemic on substance use and abuse
Addiction Recovery Among Opioid-Dependent Patients Treated With Injectable Subcutaneous Depot Buprenorphine: Study Protocol of a Non-randomized Prospective Observational Study (ARIDE), Schulte et al., 2020, Frontiers in Psychiatry.